>

NanoSyrinx in Parliament

Our Founder and CEO, Joe Healey, was invited by the Parliamentary and Scientific Committee (P&SC – https://www.scienceinparliament.org.uk/) to discuss the future and potential of Synthetic Biology for the UK and for human health.

The UK has a stated (and laudable) ambition to become a “Scientific Superpower”, and Synthetic Biology is intimately tied to that vision. It was a cornerstone of the industrial strategy under previous leadership, and is still very much at the forefront of current science policy thinking.

The panel, was organised by SynBioBeta (the largest synthetic biology community and advocacy group) and Bit.Bio (a UK ‘cell programming’ company) with the P&SC. Whilst the focus of the discussion was particularly what Synthetic Biology could offer for human health, a wide range of topics were covered including synbio for sustainability and Net Zero, as well as a discussion about what the UK entrepreneurship ecosystem needs in order to thrive.

 

The panel was chaired by Stephen Metcalfe MP (South Basildon and East Thurrock), and the speakers included (pictured left to right above):

  • Mark Kotter, CEO of Bit.bio

  • Sara Holland, Patent attorney at Potter Clarkson specialising in synbio IP

  • Stephen Metcalfe MP, chair of the session

  • Fiona Mischel, Director of Human Health content at SynBioBeta

  • Joe Healey, Founder and CEO of NanoSyrinx

Read more news

Nature Biopharma Dealmakers figure of the NanoSyrinx platform

NanoSyrinx featured in Nature Biopharma Dealmakers

NanoSyrinx is delighted to have been featured in Nature’s Biopharma Dealmakers in an in-depth article exploring how the company is engineering bacterial nanomachines into a new therapeutic modality for targeted intracellular protein delivery. The article highlights NanoSyrinx’s progress in tackling the longstanding challenge that >80% of intracellular targets remain undruggable, our platform’s ability to deliver […]

Read more
Dr Valentina Galli

NanoSyrinx strengthens senior R&D team

Appointments of Dr Valentina Galli as Associate Research Director, Translational Biology, and Steve Ruscoe as Principal Scientist, Process Development Drug delivery and process development expertise further expands the Company’s R&D capabilities Coventry, UK, 21st January 2025: NanoSyrinx, a synthetic biology company developing Nanosyringes as a novel platform for targeted intracellular delivery of biologic therapeutics, today […]

Read more

Meet our science and scientists at SITC and EORTC

Members from the NanoSyrinx team will be on the road over the coming weeks presenting exciting data from our internal developments and recent collaborations. If you’d like to learn more about our science and meet some of the talented folks responsible for it, come along to the sessions below. A copy of the poster can […]

Read more